



# What's New <sup>for the</sup> 2010 Physician Quality Reporting Initiative (PQRI)

January 2010

This fact sheet includes important information about changes to the Physician Quality Reporting Initiative (PQRI) for 2010 as authorized by the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA). A web page dedicated to providing all the latest news on PQRI is available at <http://www.cms.hhs.gov/PQRI> on the Centers for Medicare & Medicaid Services (CMS) website.

## Important Changes for the 2010 PQRI

---

The following are key changes to the 2010 PQRI:

- Introduction of an electronic health record (EHR)-based reporting mechanism;
- Addition of 30 new individual quality measures;
- Addition of six new PQRI measures groups;
- Addition of a six-month reporting period for claims-based reporting of individual measures; and
- Addition of a Group Practice Reporting Option (GPRO).

## 2010 PQRI Reporting Mechanisms

---

The number of PQRI reporting mechanisms will increase from two to three in 2010. As in 2009, eligible professionals (EPs) can submit data on individual quality measures or measures groups through claims or a qualified registry. In addition, individual EPs can submit data on a subset of individual PQRI quality measures for the 12-month period using a qualified EHR product.

### Qualified Registries

A self-nomination process to potentially qualify additional registries to submit quality measures data on behalf of EPs will be conducted for the 2010 PQRI. Registries qualified for 2009 are not required to go through the vetting process again for 2010 unless they are unsuccessful at submitting 2009 data by March 31, 2010. CMS plans to begin making the list of qualified registries for the 2010 PQRI available at <http://www.cms.hhs.gov/PQRI> on the CMS website in December 2009 and complete the list by Summer 2010.

## Qualified EHR Products

EHR products that successfully complete the 2009 EHR Testing Program will be considered qualified EHR products for the purpose of submitting data extracted from the EHRs for the 2010 PQRI. Upon conclusion of the 2009 EHR Testing Program, slated for early 2010, the list of qualified EHR products will be posted at <http://www.cms.hhs.gov/PQRI> on the CMS website.

## 2010 PQRI Individual Quality Measures

---

The 2010 PQRI consists of 175 individual quality measures. This includes 30 new measures, 46 measures that are only reportable through a qualified PQRI registry, and 10 measures available for EHR-based reporting. Four measures from the 2009 PQRI are being retired for 2010.

- [Appendix 1](#) lists four 2009 PQRI measures that are being retired for 2010.
- [Appendix 2](#) identifies 30 new individual quality measures for 2010.
- [Appendix 3](#) identifies 26 measures from the 2009 individual measures that are reportable through registries only in 2010.
  - The 20 new measures for 2010 that are reportable through registries only are identified in [Appendix 2](#).
- [Appendix 4](#) identifies the 10 measures available for EHR-based reporting.

**NOTE:** The 2010 PQRI quality measure specifications for any given individual quality measure may be different from specifications for the same quality measure used for 2009. EPs should ensure that they are using the 2010 PQRI quality measure specifications.

## 2010 PQRI Measures Groups

---

For 2010, there are a total of 13 measures groups.

Seven measures groups were retained from the 2009 PQRI: 1) Diabetes Mellitus, 2) Chronic Kidney Disease, 3) Preventive Care, 4) Rheumatoid Arthritis, 5) Coronary Artery Bypass Graft (CABG) Surgery, 6) Perioperative Care, and 7) Back Pain.

**NOTE:** One measure has been added to the Preventive Care Measures Group for 2010.

Six new measures groups were added for the 2010 PQRI:

1. Coronary Artery Disease;
2. Heart Failure;
3. Ischemic Vascular Disease;
4. Hepatitis C;
5. Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS); and
6. Community-Acquired Pneumonia.

[Appendix 5](#) lists the new measures groups and the individual measures included within each group.

In addition to the CABG Surgery Measures Group from the 2009 PQRI, the Coronary Artery Disease, Heart Failure, and HIV/AIDS Measures Groups will be reportable only through qualified registries. The measures in the Back Pain Measures Group will continue to be reportable only as a measures group and not as individual PQRI quality measures.

**NOTE:** The specifications for measures groups do not necessarily contain all the specification elements of each individual measure included in the measures group. Therefore, the specifications and instructions for measures groups will be provided separately from the specifications and instructions for the 2010 individual measures. In addition, the 2010 PQRI measures group specifications for any given measures group may be different from specifications for the same measures group used for 2009. EPs should ensure that they are using the 2010 PQRI measures group specifications.

## 2010 PQRI Reporting Options and Criteria for Satisfactory Reporting for Individual EPs

There are no changes to the criteria for satisfactory reporting of individual measures by individual EPs. However, there are minor changes to the criteria for satisfactory reporting for individual EPs who choose to report measures groups (Refer to Tables 2 and 4).

With the introduction of an EHR-based reporting mechanism and a 6-month reporting period for claims-based reporting of individual measures, there are a total of 11 reporting options available for the 2010 PQRI. An individual EP only needs to satisfactorily report using one option to qualify for a PQRI incentive payment for the applicable reporting period.

If fewer than three individual measures apply to an EP, there are only two reporting options available. The EP will be required to report on all applicable measures (one or two measures) through claims. As in previous years, an EP who reports on fewer than three individual measures may also be subject to the Measure Applicability Validation Process to make certain there are no additional measures on which the EP could have reported.

The criteria used to determine whether an EP satisfactorily reports for the 2010 PQRI are summarized in Tables 1 through 5 below.

**Table 1: Criteria for Claims-based Reporting of Individual Measures**

Reporting Criteria	Reporting Period
At least 3 PQRI measures, or 1-2 measures if less than 3, apply to the EP, for 80% of applicable Medicare Part B Fee-for-Service (FFS) patients of each EP.	January 1, 2010 – December 31, 2010
At least 3 PQRI measures, or 1-2 measures if less than 3, apply to the EP, for 80% of applicable Medicare Part B FFS patients of each EP.	July 1, 2010 – December 31, 2010

**Table 2: Criteria for Claims-based Reporting of Measures Groups**

Reporting Criteria	Reporting Period
One measures group for 30 Medicare Part B FFS patients of each EP. *	January 1, 2010 – December 31, 2010
One measures group for 80% of applicable Medicare Part B FFS patients of each EP (with a minimum of 15 patients during the reporting period). **	January 1, 2010 – December 31, 2010
One measures group for 80% of applicable Medicare Part B FFS patients of each EP (with a minimum of 8 patients during the reporting period). **	July 1, 2010 – December 31, 2010

\* For 2010, EPs are no longer required to report on patients seen consecutively by date of service, but may report on any 30 patients seen during the reporting period.

\*\* For 2010, the minimum patient sample requirement was reduced from 30 for the 12-month reporting period and 15 for the 6-month reporting period to 15 and 8, respectively.

**Table 3: Criteria for Registry-based Reporting of Individual Measures**

Reporting Criteria	Reporting Period
At least 3 PQRI measures for 80% of applicable Medicare Part B FFS patients of each EP.	January 1, 2010 – December 31, 2010
At least 3 PQRI measures for 80% of applicable Medicare Part B FFS patients of each EP.	July 1, 2010 – December 31, 2010

**Table 4: Criteria for Registry-based Reporting of Measures Groups**

Reporting Criteria	Reporting Period
One measures group for 30 patients of each EP. Patients may include, but may not be exclusively, non-Medicare Part B FFS patients. *	January 1, 2010 – December 31, 2010
One measures group for 80% of applicable Medicare Part B FFS patients of each EP (with a minimum of 15 patients during the reporting period). **	January 1, 2010 – December 31, 2010
One measures group for 80% of applicable Medicare Part B FFS patients of each EP (with a minimum of 8 patients during the reporting period). **	July 1, 2010 – December 31, 2010

\* For 2010, EPs are no longer required to report on patients seen consecutively by date of service; but may report on any 30 patients seen during the reporting period.

\*\* For 2010, the minimum patient sample requirement was reduced from 30 for the 12-month reporting period and 15 for the 6-month reporting period to 15 and 8, respectively.

**Table 5: Criteria for EHR-based Reporting of Individual Measures**

Reporting Criteria	Reporting Period
At least 3 PQRI measures, for at least 80% of the EP's Medicare Part B FFS patients seen during the reporting period to whom the measure applies.	January 1, 2010 – December 31, 2010

### **New Reporting Option for Group Practices**

Beginning with the 2010 PQRI, group practices that satisfactorily submit data on quality measures can qualify to earn a PQRI incentive payment if it is determined that the group practice satisfactorily reports data on PQRI quality measures. This incentive payment is equal to two percent of the group practice's total estimated Medicare Part B Physician Fee Schedule (PFS) allowed charges processed no later than two months after the end of the applicable 2010 reporting period. Previously, the determination of satisfactory reporting and calculation of the incentive payment amount was made only at the individual EP level. For purposes of this GPRO, a group practice consists of a single tax identification number (TIN) with 200 or more individual EPs or individual national provider identifiers (NPIs). Group practices must go through a self-nomination process and meet the requirements for participating in the 2010 PQRI GPRO.

The reporting mechanism, reporting criteria, and reporting period for satisfactory reporting under the GPRO are summarized in Table 6 below.

**Table 6: Criteria for the Group Practice Reporting Option**

Reporting Mechanism	Reporting Criteria	Reporting Period
A pre-populated data collection tool provided by CMS	Report on all 26 measures included in the data collection tool (the list of measures can be found in <a href="#">Appendix 6</a> in this document); <b>and</b> Complete the tool for the first 411 consecutively ranked and assigned beneficiaries in the order in which they appear in the group's sample for each disease module or preventive care measure. If the pool of eligible assigned beneficiaries is less than 411, then report on 100% of assigned beneficiaries.	January 1, 2010 – December 31, 2010

**NOTE:** An individual EP who is participating in the GPRO as a member of a group practice will not be able to separately earn a PQRI incentive payment as an individual EP under the same TIN (for the same TIN/NPI combination).

## Appendix 1: 2009 PQRI Measures Retired for 2010

Measure Number	Measure Title
11	Stroke and Stroke Rehabilitation: Carotid Imaging Reporting
34	Stroke and Stroke Rehabilitation: Tissue Plasminogen Activator (tPA) Considered
95	Otitis Media with Effusion (OME): Hearing Testing
152	Coronary Artery Disease (CAD): Lipid Profile in Patients with CAD

## Appendix 2: New Individual PQRI Measures in 2010 and Their Developer

Measure Number	Measure Title	Measure Developer	Available Reporting Mechanism(s) <sup>+</sup>
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	American Heart Association (AHA)/ American Stroke Association (ASA)/The Joint Commission (TJC)	R
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	Audiology Quality Consortium (AQC)	C, R
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	AQC	C, R
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	AQC	C, R
191	Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery	American Medical Association (AMA)-Physician Consortium for Performance Improvement (PCPI)/National Committee for Quality Assurance (NCQA)	R



**Appendix 2: New Individual PQRI Measures in 2010 and Their Developer (continued)**

<b>Measure Number</b>	<b>Measure Title</b>	<b>Measure Developer</b>	<b>Available Reporting Mechanism(s)<sup>+</sup></b>
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	AMA-PCPI/NCQA	R
193	Perioperative Temperature Management	AMA-PCPI	C, R
194	Oncology: Cancer Stage Documented	AMA-PCPI/American Society of Clinical Oncology (ASCO)	C, R
195	Stenosis Measurement in Carotid Imaging Studies	AMA-PCPI/NCQA	C, R
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	AMA-PCPI	R
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol	AMA-PCPI	R
198	Heart Failure: Left Ventricular Function (LVF) Assessment	AMA-PCPI	R
199	Heart Failure: Patient Education	AMA-PCPI	R
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	AMA-PCPI	R
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	NCQA	C, R
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile	NCQA	C, R
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	NCQA	C, R
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	NCQA	C, R

**Appendix 2: New Individual PQRI Measures in 2010 and Their Developer (continued)**

<b>Measure Number</b>	<b>Measure Title</b>	<b>Measure Developer</b>	<b>Available Reporting Mechanism(s)<sup>+</sup></b>
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	AMA-PCPI/NCQA	R
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	AMA-PCPI/NCQA	R
207	HIV/AIDS: Screening for Injection Drug Use	AMA-PCPI/NCQA	R
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	AMA-PCPI/NCQA	R
209	Functional Communication Measure – Spoken Language Comprehension	American Speech-Language Hearing Association (ASHA)	R
210	Functional Communication Measure – Attention	ASHA	R
211	Functional Communication Measure – Memory	ASHA	R
212	Functional Communication Measure – Motor Speech	ASHA	R
213	Functional Communication Measure – Reading	ASHA	R
214	Functional Communication Measure – Spoken Language Expression	ASHA	R
215	Functional Communication Measure – Writing	ASHA	R
216	Functional Communication Measure – Swallowing	ASHA	R

<sup>+</sup> C = Claims, R = Registry



### Appendix 3: 2010 Registry-only Measures Selected from 2009 Measures

Measure Number *	Measure Title	Measure Developer
5 *	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotension Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patient with Prior Myocardial Infarction (MI)	AMA-PCPI
8 *	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge	AMA-PCPI/NCQA
81	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis in ESRD Patients	AMA-PCPI
82	End Stage Renal Disease (ESRD): Plan of Care for Inadequate Peritoneal Dialysis	AMA-PCPI
83 *	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	AMA-PCPI
118 *	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
136 *	Melanoma: Follow-Up Aspects of Care	AMA-PCPI/NCQA
137 *	Melanoma: Continuity of Care – Recall System	AMA-PCPI/NCQA
138 *	Melanoma: Coordination of Care	AMA-PCPI/NCQA
143 *	Oncology: Medical and Radiation – Pain Intensity Quantified	AMA-PCPI
144 *	Oncology: Medical and Radiation – Plan of Care for Pain	AMA-PCPI
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	AMA-PCPI/NCQA
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	AMA-PCPI/NCQA
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	AMA-PCPI/NCQA

### Appendix 3: 2010 Registry-only Measures Selected from 2009 Measures (continued)

Measure Number *	Measure Title	Measure Developer
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	AMA-PCPI/NCQA
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)	Society of Thoracic Surgeons (STS)
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	STS
166	Coronary Artery Bypass Graft (CABG): Stroke/ Cerebrovascular Accident (CVA)	STS
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency	STS
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	STS
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	STS
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	STS
171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling	STS
174	Pediatric End Stage Renal Disease (ESRD): Plan of Care for Inadequate Hemodialysis	AMA-PCPI

\* Individual PQRI measures that were available for both claims-based and registry-based reporting in 2009, but are only available for registry-based reporting for the 2010 PQRI.

### Appendix 4: 2010 EHR-based Reporting Measures

Measure Number	Measure Title	Measure Developer
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	NCQA
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	NCQA
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	NCQA

#### Appendix 4: 2010 EHR-based Reporting Measures (continued)

Measure Number	Measure Title	Measure Developer
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	AMA-PCPI
110	Preventive Care and Screening: Influenza Immunization for patients $\geq$ 50 Years Old	AMA-PCPI
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years And Older	NCQA
112	Preventive Care and Screening: Screening Mammography	NCQA
113	Preventive Care and Screening: Colorectal Cancer Screening	NCQA
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	CMS/Quality Insights of Pennsylvania (QIP)

#### Appendix 5: New 2010 PQRI Measures Groups for Individual EPs

**Table 1: 2010 Coronary Artery Disease Measures Group\***

Measure Number	Measure Title	Measure Developer
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	AMA-PCPI
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	AMA-PCPI
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	NCQA
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	AMA-PCPI
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol	AMA-PCPI

\* This measures group is reportable through registry-based reporting only for 2010.

**Table 2: 2010 Heart Failure Measures Group\***

<b>Measure Number</b>	<b>Measure Title</b>	<b>Measure Developer</b>
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	AMA-PCPI
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	AMA-PCPI
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	NCQA
198	Heart Failure: Left Ventricular Function (LVF) Assessment	AMA-PCPI
199	Heart Failure: Patient Education	AMA-PCPI

\* This measures group is reportable through registry-based reporting only for 2010.

**Table 3: 2010 Ischemic Vascular Disease Measures Group**

<b>Measure Number</b>	<b>Measure Title</b>	<b>Measure Developer</b>
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use	AMA-PCPI
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit	NCQA
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	NCQA
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile	NCQA
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	NCQA
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	NCQA

**Table 4: 2010 Hepatitis C Measures Group**

Measure Number	Measure Title	Measure Developer
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	AMA-PCPI
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	AMA-PCPI
86	Hepatitis C: Antiviral Treatment Prescribed	AMA-PCPI
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	AMA-PCPI
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	AMA-PCPI
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	AMA-PCPI
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	AMA-PCPI
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	AMA-PCPI

**Table 5: 2010 HIV/AIDS Measures Group\***

Measure Number	Measure Title	Measure Developer
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	AMA-PCPI/NCQA
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	AMA-PCPI/NCQA
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	AMA-PCPI/NCQA
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	AMA-PCPI/NCQA
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	AMA-PCPI/NCQA
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	AMA-PCPI/NCQA
207	HIV/AIDS: Screening for Injection Drug Use	AMA-PCPI/NCQA
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	AMA-PCPI/NCQA

\* This measures group is reportable through registry-based reporting only for 2010.

**Table 6: 2010 Community-Acquired Pneumonia Measures Group**

Measure Number	Measure Title	Measure Developer
56	Community-Acquired Pneumonia (CAP): Vital Signs	AMA-PCPI/NCQA
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	AMA-PCPI/NCQA
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status	AMA-PCPI/NCQA
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic	AMA-PCPI/NCQA

**Appendix 6: Measures For Physician Groups Participating in the 2010 PQRI GPRO**

Measure Number	Measure Title	Measure Source	Measure Developer
<b>Diabetes Mellitus (DM) Disease Module (8 Measures)</b>			
GPRO DM-1	Diabetes Mellitus: Hemoglobin A1c Testing	MCMP DM-1	NCQA
GPRO DM-2	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	PQRI #1	NCQA
GPRO DM-3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	PQRI #3	NCQA
GPRO DM-5	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	PQRI #2	NCQA
GPRO DM-6	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	PQRI #119	NCQA
GPRO DM-7	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	PQRI #117	NCQA
GPRO DM-8	Diabetes Mellitus: Foot Exam	PQRI #163	NCQA
GPRO DM-9	Diabetes Mellitus: Lipid Profile	MCMP DM-9	NCQA
<b>Heart Failure (HF) Disease Module (7 Measures)</b>			
GPRO HF-1	Heart Failure: Left Ventricular Function (LVF) Assessment	PQRI #198	AMA-PCPI
GPRO HF-2	Heart Failure: Left Ventricular Function (LVF) Testing	MCMP HF-2	CMS/QIP

**Appendix 6: Measures For Physician Groups Participating in the 2010 PQRI GPRO (continued)**

<b>Measure Number</b>	<b>Measure Title</b>	<b>Measure Source</b>	<b>Measure Developer</b>
GPRO HF-3	Heart Failure: Weight Measurement	MCMP HF-3	AMA-PCPI
GPRO HF-5	Heart Failure: Patient Education	PQRI #199	AMA-PCPI
GPRO HF-6	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	PQRI #8	AMA-PCPI
GPRO HF-7	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	PQRI #5	AMA-PCPI
GPRO HF-8	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	PQRI #200	AMA-PCPI
<b>Coronary Artery Disease (CAD) Module (4 Measures)</b>			
GPRO CAD-1	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	PQRI #6	AMA-PCPI
GPRO CAD-2	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol	PQRI #197	AMA-PCPI
GPRO CAD-3	Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)	PQRI #7	AMA-PCPI
GPRO CAD-7	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	PQRI #118	AMA-PCPI
<b>Hypertension (HTN) Disease Module (3 Measures)</b>			
GPRO HTN-1	Hypertension (HTN): Blood Pressure Measurement	PGP HTN-1	AMA-PCPI
GPRO HTN-2	Hypertension (HTN): Blood Pressure Control	PGP HTN-2	NCQA



**Appendix 6: Measures For Physician Groups Participating in the 2010 PQRI GPRO (continued)**

Measure Number	Measure Title	Measure Source	Measure Developer
GPRO HTN-3	Hypertension (HTN): Plan of Care	PGP HTN-3	AMA-PCPI
<b>Preventive (Prev) Care Measures (4 Measures - Individually Sampled)</b>			
GPRO Prev-5	Preventive Care and Screening: Screening Mammography	PQRI #112	NCQA
GPRO Prev-6	Preventive Care and Screening: Colorectal Cancer Screening	PQRI #113	NCQA
GPRO Prev-7	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	PQRI #110	AMA-PCPI
GPRO Prev-8	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	PQRI #111	NCQA



This fact sheet was current at the time it was published or uploaded onto the web. Medicare policy changes frequently so links to the source documents have been provided within the document for your reference.

This fact sheet was prepared as a tool to assist providers and is not intended to grant rights or impose obligations. Although every reasonable effort has been made to assure the accuracy of the information within these pages, the ultimate responsibility for the correct submission of claims and response to any remittance advice lies with the provider of services. The Centers for Medicare & Medicaid Services (CMS) employees, agents, and staff make no representation, warranty, or guarantee that this compilation of Medicare information is error-free and will bear no responsibility or liability for the results or consequences of the use of this guide. This publication is a general summary that explains certain aspects of the Medicare Program, but is not a legal document. The official Medicare Program provisions are contained in the relevant laws, regulations, and rulings.

ICN 902964